CytoMed Therapeutics
GDTC
3 hedge funds and large institutions have $16.3K invested in CytoMed Therapeutics in 2026 Q1 according to their latest regulatory filings, with 1 funds opening new positions, 1 increasing their positions, 0 reducing their positions, and 3 closing their positions.
40% less funds holding
Funds holding: 5 → 3 (-2)
67% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 3
77% less capital invested
Capital invested by funds: $70.8K → $16.3K (-$54.4K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
XT
XTX Topco
George Town,
Cayman Islands
|
+$10.7K |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$5.39K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$39.7K |
| 2 |
TSS
Two Sigma Securities
New York
|
-$15.8K |
| 3 |
SG
StoneX Group
New York
|
-$13.8K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
XT
1
XTX Topco
George Town,
Cayman Islands
| $10.1K | +$10.7K | +10,136 | New |
|
|
2
UBS Group
Zurich,
Switzerland
| $6.18K | +$5.39K | +5,117 | +480% |
|
3
Osaic Holdings
Scottsdale,
Arizona
| $21 | – | – | – |
|
|
4
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| – | -$39.7K | -29,829 | Closed |
|
|
TSS
5
Two Sigma Securities
New York
| – | -$15.8K | -11,857 | Closed |
|
|
SG
6
StoneX Group
New York
| – | -$13.8K | -10,356 | Closed |
|
GDTC Hedge Fund Activity: Q1 2026 in Review
3 of the 8,130 institutional investors tracked by Wall St. Rank reported a position in CytoMed Therapeutics (GDTC) for Q1 2026, worth a combined $16.3K — down 77% from $70.8K a quarter earlier.
Sellers outnumbered buyers: 3 funds closed out of GDTC and 1 opened new positions — a net loss of 2 holders — while 0 trimmed existing stakes and 1 added.
The largest buyer was XTX Topco, opening a new position worth an estimated $10.7K. The largest seller was Susquehanna International Group, exiting entirely with an estimated $39.7K sold.
- 3 institutional investors held CytoMed Therapeutics (GDTC) as of Q1 2026, down from 5 in Q4 2025.
- Funds reported $16.3K of CytoMed Therapeutics stock for Q1 2026, down 77% quarter-over-quarter.
- 1 fund opened new CytoMed Therapeutics positions in Q1 2026 and 3 closed out, a net change of -2 holders.
- The largest CytoMed Therapeutics buyer in Q1 2026 was XTX Topco, an estimated $10.7K added.
- The largest CytoMed Therapeutics seller in Q1 2026 was Susquehanna International Group, an estimated $39.7K sold.
Based on aggregated 13F filings for Q1 2026.